Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

Frontiers Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

Bivalent CoV2 preS dTM-AS03 (D614 + Beta) induces broader

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein – ScienceOpen

Frontiers Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines